📋 Indications & Clinical Dosage
*Prevention of ischaemic neurological deficits following subarachnoid haemorrhage:*
ORAL: Adults: 2 tab four hrly starting within 4 days of subarachnoid haemorrhage and continue for 21 days.
*Treatment of neurological deficits following subarachnoid haemorrhage:*
BY IV INF: Adults: 1 mg/hr, by IV INF for first 2 hr, then 2 mg/hr for minimum 5 days, max 14 days. Patients weighing under 70 kg or with unstable BP, start on 0.5 mg/hr.
Children: Not recommended.
💊 Mode of Administration
Via drip tubing in D5W or NS or Compound sodium lactate. Not to be added to infusion container, ad-minister via an infusion pump through a Y-piece into a central catheter.
⚠️ Precautions & Warnings
Cerebral oedema, raised intracranial pressure, renal impairment, cirrhosis, hypotension (Infusion only). Monitor BP Nimotop infusion is incompatible with PVC.
🔄 Drug Interactions
Beta-blockers, other calcium antagonists, anti-convulsants, cimetidine.
⚠️ Adverse Reactions / Side Effects
Hypotension, flushing, headache, changes in heart rate, GI upset, transient rise in liver enzymes may occur with infusion.
🤰 Pregnancy & Lactation Safety
Pregnancy Risk:
Caution advised
Lactation / Breastfeeding:
Not recommended
🧪 Compatibility & Storage Stability
Compatibility: Incompatible with polyvinyl chloride giving sets or containers.
Stability & Storage: Nimodipine infusion solution must not be mixed with other drugs. It is advisable to continue administration of nimodipine infusion solution during anesthesia, surgery, and angiography. Protect infusion from light.
📚 Official Regulatory & Clinical References
- Drug Regulatory Authority of Pakistan (DRAP): Drug Registration, S.R.O. Price Gazettes & National Essential Medicines List (NEML).
- World Health Organization (WHO): Collaborating Centre for Drug Statistics Methodology (ATC/DDD Index).
- Formulary Standards: British National Formulary (BNF) & Pakistan National Formulary (PNF) guidelines.